Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797343 | 1.00 | SCN9A (0.58) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16143215 | 1.00 | SCN9A (0.58) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16141315 | 1.00 | SCN9A (0.58) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14934655 | 0.95 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16141316 | 0.95 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16141298 | 0.95 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16107835 | 0.95 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14934647 | 0.95 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14934452 | 0.95 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14921620 | 0.93 | SCN9A (0.49) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |